HPV Vaccine Immunity in High-risk Women

HPV Infection Clinical Trial

Official title:

Evaluation of HPV Vaccine Immunity in High-risk Women: a Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04590521
• Other study ID #: HREC 2019.225
• Status: Completed
• Phase: Phase 4
• Start date: September 14, 2022
• Est. completion date: April 19, 2023

Study information

• Verified date: January 2024
• Source: Murdoch Childrens Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm immunological study based in Vietnam. The study will examine human papillomavirus (HPV) vaccine responses in high-risk women (female-sex-worker; FSW). We aim to recruit 60 women (aged 18-25 years old) and provide them with a standard 3-dose schedule of licensed 4vHPV vaccine (Gardasil®, Merck). Blood and cervical swab samples will be collected for immunology and virology testing, respectively.

Description:

Multiple sexual partners (>4) is a risk factor for human papillomavirus (HPV) infection and cervical cancer. Due to the nature of their work, female sex workers (FSW) are at a particular high risk of HPV infection and developing cervical cancer. These groups are also likely to be reservoirs for HPV transmission since they are less likely to clear the infection and are known to be infected with multiple HPV types simultaneously. Benefits in vaccinating HPV-infected individuals, includes protecting them against HPV vaccine types that the person is not currently infected with as well as re-infection with the same HPV type. Therefore, immunising FSW with HPV vaccine is a novel strategy to reduce their risk of cervical cancer as well as downstream effects on HPV transmission. FSW is common in low-and middle-income countries (LMICs) of Asia (i.e. Vietnam), but the use of HPV vaccine in LMICs is very low often due to high costs and logistical difficulties in vaccine delivery. Furthermore, available data on the immunogenicity of HPV vaccine in FSW are limited. The aim of this study is to determine the immunogenicity of HPV vaccine in FSW and compare their antibody responses among young women (non-FSW) of the same age group by comparison with published data.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 63
• Est. completion date: April 19, 2023
• Est. primary completion date: April 19, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 25 Years

Eligibility

Inclusion Criteria:

• Each participant must meet all of the following criteria to be enrolled in this trial:
• Is between the reporting ages of 18-25 years at the time of recruitment
• Engage in commercial sex in the last month

Exclusion Criteria:

• Participants meeting any of the following criteria will be excluded from the trial:
• Pregnant or possibly pregnant
• Has received any HPV vaccine previously
• Has an axillary temperate greater than 38°C
• Known allergies to any vaccine component
• incapacity to provide consent

Related Conditions & MeSH terms

• HPV Infection
• Papillomavirus Infections

Intervention

Biological:
• Gardasil®, Merck
Gardasil® (4vHPV) is a recombinant protein particulate (VLP) vaccine. Each 0.5 mL monodose pre-filled syringe or vial contains approximately 20 µg of HPV 6 L1 protein, 40 µg of HPV 11 L1 protein, 40 µg of HPV 16 L1 protein, and 20 µg of HPV 18 L1 protein as well as approximately 225 mcg of aluminum (as Amorphous Aluminum Hydroxyphosphate Sulfate adjuvant). It has completed phase III trials and is licensed for use in over 100 countries around the world including the United States, Australia and countries in the European Union (EU) for girls aged 9-26 years. Vietnam currently offer this vaccine in private health clinics, as a 3-dose schedule (0, 2 and 6 months).

Locations

Country	Name	City	State
Vietnam	Hai Phong District Health Centre	H?i Phòng

Sponsors (3)

Lead Sponsor	Collaborator
Murdoch Childrens Research Institute	London School of Hygiene and Tropical Medicine, National Institute of Hygiene and Epidemiology, Vietnam

Country where clinical trial is conducted

Vietnam, 

References & Publications (1)

Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G; HPV-010 Study Group. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009 Oct;5(10):705-19. doi: 10.4161/hv.5.10.9518. Epub 2009 Oct 14. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Neutralising antibody (NAb) levels to HPV16	Geometric mean titres (GMT) of HPV- specific antibody responses to HPV16 at Month 7.	7 months
Primary	Neutralising antibody (NAb) levels to HPV18	Geometric mean titres (GMT) of HPV- specific antibody responses to HPV18 at Month 7.	7 months
Secondary	NAb titres to HPV16 and 18 at baseline	GMTs of NAb responses to HPV16 and 18 prior to receiving HPV vaccine	Baseline
Secondary	NAb titres to HPV16 and 18 following one dose of Gardasil	GMTs of NAb responses to HPV16 and 18 one month following the first dose of Gardasil vaccine given at baseline	Month 2
Secondary	NAb titres to HPV16 and 18 following second dose of Gardasil	GMTs of NAb responses to HPV16 and 18 one month following the second dose of Gardasil given at Month 2	Month 3
Secondary	NAb titres to HPV 52 and 58 at baseline	GMTs of NAb responses to HPV52 and 58 prior to receiving HPV vaccine	Baseline
Secondary	NAb titres to HPV52 and 58 following one dose of Gardasil	GMTs of NAb responses to HPV52 and 58 one month following the first dose of Gardasil vaccine given at baseline	Month 2
Secondary	NAb titres to HPV52 and 58 following second dose of Gardasil	GMTs of NAb responses to HPV52 and 58 one month following the second dose of Gardasil vaccine given at Month 1	Month 3
Secondary	NAb titres to HPV52 and 58 following third dose of Gardasil	GMTs of NAb responses to HPV52 and 58 one month following the third dose of Gardasil vaccine given at Month 6	Month 7
Secondary	HPV prevalence rates in FSW at baseline	The presence of HPV DNA will be measured using PCR on cervical swabs collected at baseline	Baseline
Secondary	HPV prevalence rates in FSW at 2 months	The presence of HPV DNA will be measured using PCR on cervical swabs collected at month 2	Month 2
Secondary	HPV prevalence rates in FSW at 7 months	The presence of HPV DNA will be measured using PCR on cervical swabs collected at month 7	Month 7
Secondary	NAb titres stratified by HPV prevalence at baseline	NAb titres to HPV16/18/52/58 at Month 1 stratified by HPV16/18/52/58 at baseline	Baseline
Secondary	NAb titres stratified by HPV prevalence at Month 6	NAb titres to HPV16/18/52/58 at Month 7 stratified by HPV16/18/52/58 at Month 6.	Month 7